Highest-materiality recent filing
Annovis Bio prices $15M public offering of 7.9M shares and warrants
Offering of 7,895,000 shares and warrants for 7,105,500 shares at combined price $1.90.
Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027
Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).
Annovis Bio prices $10M underwritten offering of common stock and warrants
Pricing of 5,263,156 shares and 5,263,156 warrants at $1.90 per unit, gross proceeds ~$10M.
Annovis Bio reports FY2025 net loss $1.40/sh; Phase 3 AD trial 65% enrolled
FY2025 net loss $1.40 basic and diluted EPS; R&D $25.2M, G&A $4.5M; cash $19.5M expected to fund into Q3 2026.
Annovis Bio receives DSMB approval to continue Phase 3 Alzheimer's trial of buntanetap
DSMB issued positive recommendation on buntanetap safety at 6 months; trial continues without modification.
Annovis Bio reports Q3 net loss of $0.37/share; Phase 3 AD trial fully activated at 84 sites
Cash and equivalents $15.3M as of Sep 30, 2025; plus $9.4M in Oct offerings.
Annovis Bio Q2 net loss $0.32/sh; cash $17.1M; Phase 3 AD trial advances with 38 patients randomized
Cash and cash equivalents $17.1M as of June 30, 2025, up from $10.6M at Dec 31, 2024.
NYSE accepts Annovis Bio's plan to regain listing compliance; 18-month cure period
Annovis received NYSE acceptance of its plan to regain compliance with minimum market capitalization and stockholders' equity standards.
Annovis Bio starts Phase 3 Alzheimer's trial, reports Q1 net loss $0.32 per share, cash $22.2M
First participants entered pivotal Phase 3 AD trial on Feb 5, 2025; planning 760 participants, evaluating buntanetap.
Annovis Bio receives NYSE delisting notice, market cap ~$37.9M, equity $9.3M; CFO Fricker departs
NYSE notice: 30-day avg mkt cap ~$37.9M, equity $9.3M at Dec 31, 2024, both below $50M thresholds.
Annovis Bio reports Q4/FY2024 results; launches Phase 3 AD trial with data expected mid-2026
Q4 net loss $0.43/share vs $2.24 YoY; FY net loss $2.02 basic, $2.31 diluted vs $6.23 in 2023.
Annovis Bio closes $21M public offering of 5.25M units with warrants at $4.00/unit
Offering of 5,250,000 units (1 share + 1 warrant) at $4.00 per unit; gross proceeds $21M.
Annovis Bio enters first patients into pivotal Phase 3 Alzheimer's study of buntanetap
First two patients enrolled in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.
Annovis Bio enters $50M at-the-market equity distribution agreement with Oppenheimer
Agreement allows sale of up to $50M of common stock at-the-market through Oppenheimer & Co.
Annovis Bio Q3 net loss $0.97/share; FDA clears Phase 3 studies for buntanetap in early AD
FDA granted clearance for pivotal Phase 3 studies: a 6-month symptomatic and an 18-month disease-modifying trial in early Alzheimer's disease.
FDA Clears Annovis to Start Pivotal Phase 3 Alzheimer's Studies for Buntanetap
FDA clearance to proceed with pivotal Phase 3 studies for buntanetap in early Alzheimer's disease.
Annovis Bio Q2 net loss $0.44/share; cash $12.1M; AD & PD trial data positive
Q2 2024 net loss $0.44 per share vs $1.07 YoY; operating expenses $7.8M (R&D $5.8M, G&A $2.0M).
Annovis Bio: buntanetap + GLP-1 agonist shows synergistic cognitive boost in AD mouse model
Combination of buntanetap and dulaglutide (Trulicity) restored cognitive function beyond healthy controls in Alzheimer's mouse model.
FDA approves Annovis Bio's transition to new crystal form of Buntanetap for trials
FDA approved transition to new crystalline form of Buntanetap for future clinical trials.
Warrant exercise raises $7M for Annovis Bio; 0.8M shares issued
0.8M November 2023 warrants exercised July 8-9, 2024 at $9.00 per share.
Buntanetap shows dose-dependent cognition gains; MDS-UPDRS improvements in PD Phase III
Buntanetap at 20mg significantly improved MDS-UPDRS Part II, III, II+III, and Total in PD patients diagnosed >3 years.
In early AD patients (MMSE 21-24), Buntanetap showed -3.3 point ADAS-Cog11 improvement vs baseline and -2.3 vs placebo.
Q1 2024 cash $3.1M vs $5.8M at Dec 31, 2023; runway into Q4 2024. Operating expenses $7.8M (R&D $6.5M, G&A $1.3M).
Annovis completes Phase III data unblinding for buntanetap; topline expected June
Unblinding of Phase III study of buntanetap in early Parkinson's disease completed.
Phase II/III study in MMSE 21-24 patients: buntanetap showed ADAS-Cog11 improvement of -2.36 vs placebo at 3 months.
Annovis Bio CFO Henry Hagopian resigns; CEO Maria Maccecchini named interim CFO
Henry Hagopian stepped down as CFO effective April 30, 2024, to pursue other opportunities; no disagreement with company.
Annovis Bio enters equity line with Keystone Capital for up to 2.05M shares
Company may sell up to 2,051,428 shares at market price, subject to 19.99% cap unless at-market.
Net loss Q4 2023 $22.2M vs $7.7M YoY; FY net loss $56.2M vs $25.3M.
Annovis Bio closes $3M equity offering of 316,455 shares at $9.48/share
Raised $3,000,000 gross proceeds from sale of 316,455 common shares at $9.48 per share to an institutional investor.
Data cleaning completed for phase II/III trial of buntanetap in mild to moderate Alzheimer's disease.
On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.
On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.
Maria Maccecchini will continue to serve as principal financial officer on an interim basis.
On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.
Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.
Max materiality 0.90 · Median 0.65 · Most common event other_material